301 filings
Page 5 of 16
8-K
ermw94ga
14 Jan 21
Oragenics Issues Letter to Stockholders
7:14am
8-K
wxj6m0tq72jiel7r0d
7 Jan 21
Oragenics Enters into Material Transfer Agreement with Adjuvance Technologies for COVID-19 Vaccine Adjuvant
7:22am
8-K
cf1m2qnjbm8d9gzqmytk
29 Dec 20
Oragenics Announces Closing of $6.5 Million Registered Direct Offering
4:17pm
8-K
jlqkhd3q3x
28 Dec 20
Oragenics, Inc. Announces $6.5 Million Registered Direct Offering
5:04pm
8-K
5flaez32fz 4sph6tv
24 Nov 20
Oragenics Announces Closing of $6.0 Million Underwritten Public Offering
11:59am
8-K
6sxdpa 1f0
20 Nov 20
Oragenics Prices $5.25 Million Common Stock Offering
8:44am
8-K
q3prt2xuzb4b8vhmp
19 Nov 20
Oragenics Announces Proposed Underwritten Public Offering
5:18pm
8-K
bi1632r p2l3mg3
10 Nov 20
Regulation FD Disclosure
4:35pm
8-K
j88h4 cim1ir7
6 Oct 20
FDA Broadly Supports Oragenics’ Pre-IND Development Program for its SARS-CoV-2 Vaccine
7:48am
8-K
ncubslfgmx5f2rd7mdd
28 Sep 20
Oragenics Provides an Update on Funding for its SARS-CoV-2 Vaccine
7:45am
8-K
gnxxbaf
11 Sep 20
Oragenics Inc. to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference
8:53am
8-K
vfiuqc
24 Aug 20
Submission of Matters to a Vote of Security Holders
4:06pm
8-K
2w7z6ttzhc yb1unv
20 Aug 20
Other Events
8:54am
8-K
r2nni
18 Aug 20
Regulation FD Disclosure
7:55am
8-K/A
3qz6t4 qlng6
14 Aug 20
Financial Statements and Exhibits
4:22pm
8-K
mufsah2ouxbp28gsjdx
27 Jul 20
Other Events
7:49am
8-K
k0q tua34j33t
22 Jul 20
Regulation FD Disclosure
7:58am
8-K
lbti3r
10 Jul 20
Oragenics Provides Update on SARS-CoV-2 (COVID-19) Program
7:49am
8-K
5gt4s9jxxjqzyf
5 Jun 20
Entry into a Material Definitive Agreement
4:00pm
8-K/A
5x5z571 4sy
29 May 20
Audited Financial Statements
4:05pm